TG Therapeutics Inc - Asset Resilience Ratio
TG Therapeutics Inc (TGTX) has an Asset Resilience Ratio of 5.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TGTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how TG Therapeutics Inc's Asset Resilience Ratio has changed over time. See what is TG Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down TG Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TGTX stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $57.50 Million | 5.61% |
| Total Liquid Assets | $57.50 Million | 5.61% |
Asset Resilience Insights
- Limited Liquidity: TG Therapeutics Inc maintains only 5.61% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TG Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare TG Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for TG Therapeutics Inc (2003–2024)
The table below shows the annual Asset Resilience Ratio data for TG Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 22.69% | $131.11 Million | $577.69 Million | -15.10pp |
| 2023-12-31 | 37.80% | $124.58 Million | $329.59 Million | +7.12pp |
| 2022-12-31 | 30.67% | $59.37 Million | $193.57 Million | +26.49pp |
| 2021-12-31 | 4.18% | $15.88 Million | $379.63 Million | -4.13pp |
| 2020-12-31 | 8.31% | $51.99 Million | $625.64 Million | -8.74pp |
| 2019-12-31 | 17.05% | $27.80 Million | $163.01 Million | -15.06pp |
| 2018-12-31 | 32.11% | $26.85 Million | $83.62 Million | +3.36pp |
| 2017-12-31 | 28.75% | $28.00 Million | $97.38 Million | -7.49pp |
| 2016-12-31 | 36.24% | $19.85 Million | $54.78 Million | +16.71pp |
| 2015-12-31 | 19.53% | $22.17 Million | $113.47 Million | -7.05pp |
| 2014-12-31 | 26.59% | $23.06 Million | $86.75 Million | +16.31pp |
| 2013-12-31 | 10.28% | $4.95 Million | $48.11 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $22.07 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $15.91 Million | -- |
| 2008-12-31 | 58.45% | $730.00K | $1.25 Million | +49.46pp |
| 2005-12-31 | 8.99% | $1.01 Million | $11.21 Million | -70.91pp |
| 2004-12-31 | 79.90% | $4.51 Million | $5.65 Million | +75.39pp |
| 2003-12-31 | 4.52% | $352.15K | $7.80 Million | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndro… Read more